<scp>CD</scp>200 is a useful diagnostic marker for identifying atypical chronic lymphocytic leukemia by flow cytometry

Ting, Yu-Heng; Smith, Sandy; Brown, David A.; Dodds, Anthony J.; Fay, Keith; F., D. D.; Milliken, Samuel; Moore, John J.; Sewell, William A.

doi:10.1111/ijlh.12857

Cited by 22 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD43 can be expressed on the surface of B-cells and be increased during the activation and differentiation of B-cells (Wiken, Björck, Axelsson, & Perlmann, 1988). Research has shown that the rate of CD43 and CD200 coexpression in CLL and atypical CLL patients can be increased compared with MZL (Arlindo et al, 2017;Falay et al, 2018;Ting et al, 2018). Since CD5 and CD19 can be expressed in patients with CLL and MZL, evaluating the expression of CD43 and CD200 may be useful in differentiating CLL from MZL.…”

Section: Cd200mentioning

confidence: 99%

CD markers variations in chronic lymphocytic leukemia: New insights into prognosis

Vosoughi

Bagheri

Hosseinzadeh

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is one of the most commonly occurring adult leukemias that is associated with clonal accumulation of mature apoptosis-resistant B-cells in bone marrow, peripheral blood, and specific tissues. Different pathogenesis factors can contribute to the aggression of the clinical course in this disease.Cytogenetic abnormalities and surface biomarkers of neoplastic CLL cells can be effective in the outcome of CLL, and the examination of changing CD markers expressions in the progression of CLL can be related to the prognosis of this disease. Changing expression levels of CD markers on lymphocytes and other cells in CLLpatients can play a role in the aggressive clinical outcomes such as organomegaly, immunodeficiency, and advanced disease stages through their interaction with CLL microenvironment. Given the involvement of CD markers in the pathogenesis of CLL, it can be stated that recognizing the expression changes of CD markers in the cells involved in CLL can be a proper approach to evaluate prognosis among these patients.

show abstract

Section: Cd200mentioning

confidence: 99%

CD markers variations in chronic lymphocytic leukemia: New insights into prognosis

Vosoughi

Bagheri

Hosseinzadeh

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…37 Ting et al found that CD200 was a powerful tool in distinguishing CLL from MCL by FCM, particularly when distinguishing between atypical CLL and MCL. 38 In this study, all 63 CLL samples, including 7 atypical CLL samples, expressed CD200, whereas the CD200 expression of 6 MCL samples was dim or negative. Matutes scores of atypical CLL samples were ≤3, and all cases were negative for t (11:14) translocation and characteristics of MCL.…”

Section: Cd200mentioning

confidence: 48%

Measurable residual disease in the treatment of chronic lymphocytic leukemia

Uchiyama

Yokoyama

Aoki

2020

J Clin Exp Hematopathol

View full text Add to dashboard Cite

Treatment outcomes of chronic lymphocytic leukemia (CLL) have improved since chemoimmunotherapy and novel drugs became available for CLL treatment; therefore, more sensitive methods to evaluate residual CLL cells in patients are required. Measurable residual disease (MRD) has been assessed in several clinical trials on CLL using flow cytometry, real-time quantitative PCR (RQ-PCR) with allele-specific oligonucleotide (ASO) primers, and high-throughput sequencing. MRD assessment is useful to predict the treatment outcomes in the context of chemotherapy and treatment with novel drugs such as venetoclax. In this review, we discuss major techniques for MRD assessment, data from relevant clinical trials, and the future of MRD assessment in CLL treatment.

show abstract

“…Forty‐three articles and meeting abstracts (Alapat et al, ; Arlindo, Marcondes, Fernandes, & Faulhaber, ; Aytan et al, ; Brunetti et al, ; Challagundla, Medeiros, Kanagal‐Shamanna, Miranda, & Jorgensen, ; D'Arena et al, ; Debord et al, ; Dorfman & Shahsafaei, ; El Desoukey, Afify, Amin, & Mohammed, ; El Din Fouad, Ibrahim, Abdel Aziz, & Ibrahim, ; Espinet et al, ; Falay et al, ; Fan et al, ; Fanoni et al, ; Favre et al, ; Hu et al, ; Köhnke et al, ; Lesesve et al, ; Mason, Pozdnyakova, Li, Dudley, & Dorfman, ; Miao et al, ; Miguet et al, ; Mongeau‐Marceau et al, ; Montesdeoca et al, ; Mora et al, ; Palumbo et al, ; Pillai et al, ; Poongodi, Varma, Naseem, Parveen, & Varma, ; Rahman et al, ; Rahman, Kumar, Gupta, Singh, & Nityanand, ; Rawstron et al, ; Rawstron et al, ; Rawstron et al, ; Sallam, Elsalakawy, El‐Sewefy, & Khattab, ; Sandes et al, ; Sorigue, Franch‐Sarto, Sarrate, & Junca, ; Sorigue, Juncà, et al, ; Sorigue, Junca, & Granada, ; Sorigue, Raya, et al, ; Spacek et al, ; Starostka et al, ; Ting et al, ; van Dongen et al, ; Ye et al, ) were read in full, of which 16 were excluded (Figure S1). Therefore, 27 studies (5,764 patients) were included.…”

Section: Resultsmentioning

confidence: 99%

Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia

Sorigué

Magnano

Miljković

et al. 2019

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background The role of CD200 in the differential diagnosis of chronic lymphocytic leukemia (CLL) and classical mantle cell lymphoma (MCL) is well established. Its role in the differential diagnosis of CLL and other lymphoproliferative disorders (LPD) is less clear, in particular its positive predictive value (PPV). Materials and methods We conducted a systematic review of the use of CD200 in the differential diagnosis of CLL, MCL, and other predominantly leukemic, typically CD103‐negative LPD. With the results, we then derived a curve to determine the PPV based on the prevalence of the disorders included in the differential diagnosis. Results Of 43 publications screened, 27 were included in the systematic review (5,764 patients). The median CD200 positivity rate in all studies and the percentage of CD200‐positive (pooled) patients was 100% and 95% (3,061/3,208) in CLL, 4 and 8% (86/1112) in MCL and 56 and 62% (425/689) in other LPD. Conclusion CD200 is suboptimal for the differential diagnosis of CLL and disorders other than nodal MCL.

show abstract

CD200 is a useful diagnostic marker for identifying atypical chronic lymphocytic leukemia by flow cytometry

Abstract: CD200 proved to be a useful marker for differentiation between CLL and MCL by flow cytometry. In particular, CD200 was useful in distinguishing CLL samples with atypical immunophenotypes from MCL.

Cited by 22 publications

References 29 publications

CD markers variations in chronic lymphocytic leukemia: New insights into prognosis

CD markers variations in chronic lymphocytic leukemia: New insights into prognosis

Measurable residual disease in the treatment of chronic lymphocytic leukemia

Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia

Contact Info

Product

Resources

About